Efficacy and Tolerability of Travoprost 0.004%Timolol 0.5% Fixed-Dose Combination for the Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Inadequately Controlled with Beta-Blocker Monotherapy
المؤلفون المشاركون
Park, Ki H.
Hubatsch, Douglas A.
Lerner, Simon Fabian
Erichev, Valeriy
Paczka, Jose A.
Roberts, Timothy V.
المصدر
العدد
المجلد 2017، العدد 2017 (31 ديسمبر/كانون الأول 2017)، ص ص. 1-8، 8ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2017-01-23
دولة النشر
مصر
عدد الصفحات
8
التخصصات الرئيسية
الملخص EN
Objective.
To evaluate the efficacy and tolerability of travoprost 0.004%/timolol 0.5% fixed-dose combination (TTFC) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) inadequately controlled on beta-blocker monotherapy.
Methods.
In this phase IV, open-label study, 156 patients on beta-blocker monotherapy with mean intraocular pressure (IOP) between 18 and 32 mmHg were randomized (no washout period) to receive TTFC for 8 weeks (TTFC group) or to continue beta-blocker monotherapy for 4 weeks followed by TTFC for the remaining 4 weeks (beta-blocker group).
Results.
The mean IOP (±standard deviation) at baseline in the TTFC and beta-blocker groups was 22.5±2.5 mmHg and 22.2±2.3 mmHg, respectively, and at weeks 4 and 8, was 16.7±3.1 mmHg and 16.1±3.1 mmHg, respectively, in TTFC group and 21.1±3.1 mmHg and 16.1±2.8 mmHg, respectively, in the beta-blocker group.
There was a significant least squares mean difference between TTFC and beta-blocker in 8 a.m.
IOP at week 4 (−4.6 mmHg; one-sided 95% confidence interval [−inf, −3.9]; p<0.0001 [primary endpoint]); the upper bound of the 95% confidence interval was within the prespecified limit (<0).
Both treatments were well tolerated.
Conclusion.
Superior IOP control was achieved with TTFC in patients with OAG or OHT previously uncontrolled with beta-blockers.
No new safety findings were identified.
This trial is registered with ClinicalTrials.gov NCT02003391.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Lerner, Simon Fabian& Park, Ki H.& Hubatsch, Douglas A.& Erichev, Valeriy& Paczka, Jose A.& Roberts, Timothy V.. 2017. Efficacy and Tolerability of Travoprost 0.004%Timolol 0.5% Fixed-Dose Combination for the Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Inadequately Controlled with Beta-Blocker Monotherapy. Journal of Ophthalmology،Vol. 2017, no. 2017, pp.1-8.
https://search.emarefa.net/detail/BIM-1184582
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Lerner, Simon Fabian…[et al.]. Efficacy and Tolerability of Travoprost 0.004%Timolol 0.5% Fixed-Dose Combination for the Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Inadequately Controlled with Beta-Blocker Monotherapy. Journal of Ophthalmology No. 2017 (2017), pp.1-8.
https://search.emarefa.net/detail/BIM-1184582
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Lerner, Simon Fabian& Park, Ki H.& Hubatsch, Douglas A.& Erichev, Valeriy& Paczka, Jose A.& Roberts, Timothy V.. Efficacy and Tolerability of Travoprost 0.004%Timolol 0.5% Fixed-Dose Combination for the Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Inadequately Controlled with Beta-Blocker Monotherapy. Journal of Ophthalmology. 2017. Vol. 2017, no. 2017, pp.1-8.
https://search.emarefa.net/detail/BIM-1184582
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1184582
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر